IBRX
ImmunityBio (IBRX) Financial Statements
Review ImmunityBio (IBRX) financials with server-rendered company data, supporting context and links to related investor research.
- Annual revenue
- $113.29M
- Annual gross profit
- $112.54M
- Annual operating income
- $-256.03M
- Annual net income
- $-351.47M
- Annual free cash flow
- $-308.78M
- Total assets
- $501.90M
- Total liabilities
- $1.00B
- Shareholder equity
- $-499.57M
ImmunityBio (IBRX) Financial Statements research
The ImmunityBio financials page brings together the latest available annual and trailing figures for revenue, profitability, cash generation and balance-sheet strength. Comparing these measures across reporting periods can reveal whether operating performance and financial resilience are improving or weakening.
Revenue and earnings should be assessed together with free cash flow, assets, liabilities and debt ratios. A single figure is not a complete investment thesis, so use the linked analysis and valuation pages to place the reported results in context.